GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Debt-to-Revenue

CLLS (Cellectis) Debt-to-Revenue : 1.41 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cellectis Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Cellectis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $13.73 Mil. Cellectis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $77.79 Mil. Cellectis's annualized Revenue for the quarter that ended in Sep. 2024 was $64.80 Mil. Cellectis's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 1.41.


Cellectis Debt-to-Revenue Historical Data

The historical data trend for Cellectis's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Debt-to-Revenue Chart

Cellectis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.13 2.09 3.32 3.95 112.66

Cellectis Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 135.40 75.14 5.20 2.83 1.41

Competitive Comparison of Cellectis's Debt-to-Revenue

For the Biotechnology subindustry, Cellectis's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cellectis's Debt-to-Revenue falls into.



Cellectis Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Cellectis's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(13.664 + 71.392) / 0.755
=112.66

Cellectis's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(13.725 + 77.791) / 64.8
=1.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Cellectis Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cellectis's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis Business Description

Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.